menu

Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings

1.00 credits
60 minutes

CME/CE Broadcast Replay

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting. 

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all relevant financial relationships listed for these individuals have been mitigated.

    Academy staff and planners have no relevant financial relationships with any ineligible companies.

    External Reviewer Disclosures
    Oxana Megherea, PharmD, BCOP

    Dr. Megherea has no relevant financial relationships with any ineligible companies.

    Nurse Planner
    Suzanne Penna, MSN, RN, OCN®
    Office Practice Nurse Supportive Care, MSK Monmouth

    Susanne Penna discloses the following relevant financial information with an ineligible company:
    Speaker’s Bureau: EMD Serono

    Faculty Disclosure
    Patricia Mangan, MSN, CRNP

    Ms. Mangan discloses the following relevant financial information with ineligible companies:
    Speaker's Bureau: BMS, Janssen, Karyopharm, Pfizer, Amgen, Takeda

  • Target Audience

    This activity is designed for oncology nurses, nurse practitioners and navigators engaged in the care of patients with multiple myeloma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Review evolving treatment options in RRMM and clinical implications
    2. Examine how academic and tertiary care centers have integrated new treatments into practice in the setting of RRMM
    3. Identify the most common and the unique chronic toxicities associated with long-term treatment of multiple myeloma
    4. Describe the core principles surrounding mitigating and managing chronic toxicities in patients being treated in the RRMM setting
    5. Outline the expanding roles of nurses, APPS, and nurse navigators when patients are treated with newer options in the RRMM setting 
  • Accreditation and Credit Designation Statements

    In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    ANCC Contact Hours American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours, includes 0.75 pharmacology hours.

    Provider approved by the California Board of Registered Nursing.

    California BRN Provider # CEP16993

  • Implicit Bias

    Implicit bias refers to unconscious attitudes and stereotypes that influence our thoughts, judgements, decisions, and actions without our awareness. Everyone is susceptible to implicit bias, even clinicians.  In healthcare, implicit biases can have a significant impact on the quality of care an individual receives.  These biases, can be both favorable and unfavorable, and are activated involuntarily without an individual’s awareness or intentional control.  Studies have indicated that healthcare providers’ incorrect perceptions can impact providers’ communications and clinical decision-making contributing to disparities in clinical outcomes. Addressing implicit biases in healthcare is critical to improving health outcomes and promoting health equity for all patients. Patient-centered care can reduce the impact of implicit bias, by treating each patient as a unique individual who may or may not hold beliefs associated with their backgrounds and circumstances.  In addition, recognizing implicit bias in one’s own practice using techniques such as self-reflection and mindful clinical decision-making can ensure more equitable and effective care to all patients.  

    Over the past several decades, cognitive science research has demonstrated human behavior, beliefs and attitudes are shaped by automatic and unconscious cognitive processes.  The healthcare profession is devoting greater attention to how these automatic and unconscious processes impact care including:  (1) preferential treatment toward or against specific patient populations causing healthcare inequities, (2) influence patient-provider communications leading to misunderstandings and mistrust, and (3) impact access to  healthcare and affect treatment decisions resulting in misdiagnosis, delays in treatment and specialty referrals and poor pain management. Considering one might have unconscious biases and exploring them may be uncomfortable because the very idea that they exist may conflict with how clinicians perceive themselves.  It is only by becoming aware of one’s unconscious biases that members of the healthcare team can take steps to mitigate them to ensure all their patients are treated receive quality healthcare.

  • Disclosure of Unlabeled Use

    This presentation includes mention of medications that are not currently indicated in RRMM.

    The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported through an educational grant from Sanofi, Legend Biotech, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up–to date in this very dynamic setting. 

  • Disclosure of Conflicts of Interest

    According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all relevant financial relationships listed for these individuals have been mitigated.

    Academy staff and planners have no relevant financial relationships with any ineligible companies.

    External Reviewer Disclosures
    Oxana Megherea, PharmD, BCOP

    Dr. Megherea has no relevant financial relationships with any ineligible companies.

    Nurse Planner
    Suzanne Penna, MSN, RN, OCN®
    Office Practice Nurse Supportive Care, MSK Monmouth

    Susanne Penna discloses the following relevant financial information with an ineligible company:
    Speaker’s Bureau: EMD Serono

    Faculty Disclosure
    Patricia Mangan, MSN, CRNP

    Ms. Mangan discloses the following relevant financial information with ineligible companies:
    Speaker's Bureau: BMS, Janssen, Karyopharm, Pfizer, Amgen, Takeda

  • Target Audience

    This activity is designed for oncology nurses, nurse practitioners and navigators engaged in the care of patients with multiple myeloma.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Review evolving treatment options in RRMM and clinical implications
    2. Examine how academic and tertiary care centers have integrated new treatments into practice in the setting of RRMM
    3. Identify the most common and the unique chronic toxicities associated with long-term treatment of multiple myeloma
    4. Describe the core principles surrounding mitigating and managing chronic toxicities in patients being treated in the RRMM setting
    5. Outline the expanding roles of nurses, APPS, and nurse navigators when patients are treated with newer options in the RRMM setting 
  • Accreditation and Credit Designation Statements

    In support of improving patient care, American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

    ANCC Contact Hours American Academy of CME, Inc., designates this educational activity for 1.0 ANCC contact hours, includes 0.75 pharmacology hours.

    Provider approved by the California Board of Registered Nursing.

    California BRN Provider # CEP16993

  • Implicit Bias

    Implicit bias refers to unconscious attitudes and stereotypes that influence our thoughts, judgements, decisions, and actions without our awareness. Everyone is susceptible to implicit bias, even clinicians.  In healthcare, implicit biases can have a significant impact on the quality of care an individual receives.  These biases, can be both favorable and unfavorable, and are activated involuntarily without an individual’s awareness or intentional control.  Studies have indicated that healthcare providers’ incorrect perceptions can impact providers’ communications and clinical decision-making contributing to disparities in clinical outcomes. Addressing implicit biases in healthcare is critical to improving health outcomes and promoting health equity for all patients. Patient-centered care can reduce the impact of implicit bias, by treating each patient as a unique individual who may or may not hold beliefs associated with their backgrounds and circumstances.  In addition, recognizing implicit bias in one’s own practice using techniques such as self-reflection and mindful clinical decision-making can ensure more equitable and effective care to all patients.  

    Over the past several decades, cognitive science research has demonstrated human behavior, beliefs and attitudes are shaped by automatic and unconscious cognitive processes.  The healthcare profession is devoting greater attention to how these automatic and unconscious processes impact care including:  (1) preferential treatment toward or against specific patient populations causing healthcare inequities, (2) influence patient-provider communications leading to misunderstandings and mistrust, and (3) impact access to  healthcare and affect treatment decisions resulting in misdiagnosis, delays in treatment and specialty referrals and poor pain management. Considering one might have unconscious biases and exploring them may be uncomfortable because the very idea that they exist may conflict with how clinicians perceive themselves.  It is only by becoming aware of one’s unconscious biases that members of the healthcare team can take steps to mitigate them to ensure all their patients are treated receive quality healthcare.

  • Disclosure of Unlabeled Use

    This presentation includes mention of medications that are not currently indicated in RRMM.

    The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported through an educational grant from Sanofi, Legend Biotech, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule20 Jul 2024